Compounds > 2,4-bis(n,n'-di(carboxymethyl)aminomethyl)fluorescein
Page last updated: 2024-12-07

2,4-bis(n,n'-di(carboxymethyl)aminomethyl)fluorescein

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,4-bis(N,N'-di(carboxymethyl)aminomethyl)fluorescein: bone marking fluorescent dye [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID102942
MeSH IDM0117619

Synonyms (15)

Synonym
einecs 221-564-6
3147-15-7
2-[[4'-[[bis(carboxymethyl)amino]methyl]-3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-2'-yl]methyl-(carboxymethyl)amino]acetic acid
glycine, n,n'-((3',6'-dihydroxy-3-oxospiro(isobenzofuran-1(3h),9'-(9h)xanthene)-2',4'-diyl)bis(methylene))bis(n-(carboxymethyl)-
n,n'-((3',6'-dihydroxy-3-oxospiro(isobenzofuran-1(3h),9'-(9h)xanthene)-2',4'-diyl)bis(methylene))bis(n-(carboxymethyl)glycine)
2',4'-bis(n,n'-di(carboxymethyl)aminomethyl)fluorescein
2,4-bis(n,n'-di(carboxymethyl)aminomethyl)fluorescein
2,4-bis-[n,n'-di-(carboxymethyl)-aminomethyl]fluorescein
glycine, n,n'-[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3h),9'-[9h]xanthene]-2',4'-diyl)bis(methylene)]bis[n-(carboxymethyl)-
4',5'-bis[n,n-bis(carboxymethyl)aminomethyl]fluorescein
2,2',2'',2'''-(3',6'-dihydroxy-3-oxo-3h-spiro[isobenzofuran-1,9'-xanthene]-2',4'-diyl)bis(methylene)bis(azanetriyl)tetraacetic acid
FT-0756579
2,2',2'',2'''-[(3',6'-dihydroxy-3-oxo-3h-spiro[2-benzofuran-1,9'-xanthene]-2',4'-diyl)bis(methylenenitrilo)]tetraacetic acid
DTXSID50953476
4',5'-bis(n',n'-di-(carboxymethyl)aminomethyl)fluorescein
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's1 (14.29)18.2507
2000's1 (14.29)29.6817
2010's0 (0.00)24.3611
2020's4 (57.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.16 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
erythrosine
Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.		2.6730
alizarin
[no description available]		1.9710dihydroxyanthraquinonechromophore;
dye;
plant metabolite
durapatite
Durapatite: The mineral component of bones and teeth; it has been used therapeutically as a prosthetic aid and in the prevention and treatment of osteoporosis.. hydroxylapatite : A phosphate mineral with the formula Ca5(PO4)3(OH).		1.9710
oxytetracycline, anhydrous
Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Cytomegalic Inclusion Disease
[description not available]		02.610
Cytomegalovirus Infections
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.		02.610
Bone Loss, Osteoclastic
[description not available]		01.9610
Alveolar Bone Atrophy
[description not available]		01.9710